Two Sigma Investments
ADAP

Two Sigma Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Two Sigma Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-135,947
Closed -$26.8K – 3155
2025
Q1 		$26.8K Buy
135,947
+59,600
+78% +$30.9K ﹤0.01% 3085
2024
Q4 		$41.1K Buy
76,347
+19,146
+33% +$14K ﹤0.01% 3062
2024
Q3 		$54.4K Buy
+57,201
New +$64.9K ﹤0.01% 2965
2024
Q2 		– Sell
-14,474
Closed -$22.9K – 2996
2024
Q1 		$22.9K Buy
+14,474
New +$17.5K ﹤0.01% 2924
2023
Q4 		– Sell
-60,074
Closed -$46.9K – 3117
2023
Q3 		$46.9K Sell
60,074
-50,100
-45% -$42K ﹤0.01% 2824
2023
Q2 		$102K Buy
110,174
+94,774
+615% +$113K ﹤0.01% 2756
2023
Q1 		$16.8K Sell
15,400
-7,200
-32% -$11.2K ﹤0.01% 2861
2022
Q4 		$33K Buy
+22,600
New +$36.6K ﹤0.01% 2640
2022
Q2 		– Sell
-263,960
Closed -$544K – 2454
2022
Q1 		$544K Buy
+263,960
New +$712K ﹤0.01% 1980

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments's ADAP Position: Q2 2025 in Review

Two Sigma Investments sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 135,947 shares — an estimated $26.8K sold.

Two Sigma Investments first reported a position in ADAP in Q1 2022 and held it in 9 quarters. The position peaked at $544K in Q1 2022. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Two Sigma Investments reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Investments sold 135,947 Adaptimmune Therapeutics shares in Q2 2025, an estimated $26.8K.
  • Two Sigma Investments first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 9 quarters.
  • Two Sigma Investments's Adaptimmune Therapeutics position peaked at $544K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.